Older adults with type 2 diabetes face a difficult trade-off: they are among the most vulnerable to medication-related harms yet are often underrepresented in the clinical trials that guide treatment decisions. A new study led by Yuan Lu, ScD, helps address this gap by providing large-scale, real-world evidence about the safety of commonly used diabetes medications. The study was co-led by Marc Suchard, Ph.D., of the University of California, Los Angeles, who also served as the study’s corresponding author.
This article was originally published on MedicalXpress.com
